Focus on Mucosal Dosage Form R&D and Production: Custom Formulation and Large‑Scale Manufacturing Services

Wuhan Jinglong Biotechnology Co., Ltd. is a comprehensive service provider specializing in the R&D and large‑scale production of pet mucosal dosage forms. As consumer awareness of oral dissolvable films and fast‑dissolving films rises rapidly, a growing number of pet brands are turning their attention to this dosage‑form track. Nevertheless, the R&D of mucosal films involves multiple professional procedures, including the selection of film‑forming materials, formulation stability testing, release‑rate regulation, and flavor encapsulation optimization. For brands, building an in‑house technical team and production line from scratch demands lengthy cycles, heavy capital investment, and carries high trial‑and‑error costs. Against this backdrop, OEM service providers for mucosal dosage forms have become vital partners for brands aiming to bring products to market.

R&D Customization: Technical Support for Dosage‑Form Differentiation

The core strength of Wuhan Jinglong Biotechnology Co., Ltd.’s R&D services lies in its flexible and tailored solution capabilities. Client brands hold diverse product positioning: some prioritize rapid onset of action, others sustained release, and many focus on palatable flavors. The Company can adjust dosage‑form structures, release rates and nutritional ratios in accordance with client requirements. It delivers proprietary formulations via differentiated tuning across dimensions such as flavor preference, nutritional focus and target pet groups, so as to satisfy diverse demands for differentiated products.

Quality Control System: Full‑chain Assurance from Raw Materials to Finished Goods

Consistent quality control serves as the fundamental threshold for the Company’s services. Within the pet nutrition sector, batch‑to‑batch variations directly damage brand reputation and consumer trust. Medical‑grade quality‑control standards are implemented across the board, covering the full workflow of raw‑material screening, manufacturing processing and finished‑product testing. The Company holds dual certifications for HACCP (Hazard Analysis and Critical Control Points) and ISO22000 Food Safety Management System. It has passed third‑party compliance audits conducted by Bureau Veritas (BV). Its whole‑process operations benchmark against US FDA current Good Manufacturing Practice (cGMP), and the facility is registered with the US FDA as a pet‑food manufacturing site. Quality stability is strictly monitored from raw‑material warehousing through finished‑product delivery. For brand partners, this allows them to concentrate more resources on product positioning and marketing strategies, while professional teams take charge of quality control and ease the burden of in‑house management.

Production Capacity: Automated Production Lines and Reliable Delivery

Stable production capacity determines whether brands can fulfill orders promptly amid growing market demand. The deployment of automated production lines markedly boosts mass‑production efficiency. Automated processes guarantee uniform film thickness across batches, enabling tighter control over film quality and minimizing inter‑batch discrepancies. Meanwhile, the mature production‑line system supports flexible capacity allocation for brand partners. Small‑batch trials, medium‑batch pilot production and large‑volume deliveries can all be accomplished within one integrated system, lowering technical barriers for the transition from pilot to mass production.

End‑to‑end Services: Shorten Lead Time from Concept to Shelves

Covering formula R&D, forming processing and bulk delivery, the full‑chain service enables brands to obtain finished‑product outputs merely by finalizing product positioning and marketing planning. This cooperation model effectively shortens product lead time from concept to retail shelves, and meets brands’ R&D and manufacturing needs for rapid market response. Going forward, as long‑acting pet nutritional supplement categories keep expanding, collaboration efficiency between the Company and its brand partners will stand as one of the key factors determining the rapid large‑scale roll‑out of such product categories.